Infusystems Holdings, Inc. · AMEX:INFU
Infusystems — Q2 2026 Earnings Presentation
27 slides from Infusystems's earnings presentation, Aug 4, 2026
Slide 1: Helping People Live Healthier and Longer Lives
Helping People Live Healthier and Longer Lives Investor Presentation August 4, 2026 | NYSE American: INFU 1
Slide 2: Forward-Looking Statements / Non-GAAP Measures
Forward-Looking Statements / Non-GAAP Measures Forward-Looking Statements Non-GAAP Measures Certain statements contained in this presentation are forward-looking statements within the This presentation contains information prepared in conformity with GAAP as well as meaning of Section 27A of the Sec
Slide 3: InfuSystem at a Glance
InfuSystem at a Glance A home healthcare services platform enabling complex therapies outside the hospital with embedded reimbursement, logistics and clinical support Our Ecosystem Physician / Hospital Prescribes therapy; partners with InfuSystem to deliver outside the hospital Patient PLATFORM Paye
Slide 4: InfuSystem at a Glance: Scale and Market Position
InfuSystem at a Glance Scaled platform with strong penetration across providers, payers and patients Scale 450 + Employees 4,500 100k+ Customer Locations Device Fleet Market Position Coverage 18 ~70 % Market Share in 800 + Out of the Top 20 Payer Contracts Serving nearly 4,500 customer locations wit
Slide 5: InfuSystem at a Glance: 2025 Financial Performance
InfuSystem at a Glance 2025 strong financial performance and profitability expansion Most Recent Completed Fiscal Year Consistent Growth Margin Expansion Cash Generation & Reserves $143.4M Net Revenue 21.9% Adj. EBITDA Margin $24.4M Operating Cash Flow +6% YoY +3.1% YoY +19% YoY $31.5M Adj. EBITDA 8
Slide 6: Key Investor Considerations
Why InfuSystem Today: Key Investor Considerations 1. Scalable Platform With Multiple Growth Vectors • Seven consecutive years of record revenue (11% CAGR) • Capital-efficient expansion into adjacent therapies • $58.2M liquidity supports growth and selective tuck-in acquisitions 2. Meaningful Margin
Slide 7: One Shared Platform, Two Revenue Engines
One Shared Platform, Two Revenue Engines Scalable business models driving recurring revenue, margin expansion and diversified growth Clinical Biomedical Support Services Patient Services Device Solutions Primary Driver of Growth Infrastructure-Based, & Margin Expansion Contracted Revenue Therapies D
Slide 8: Revenue Platform Economics
Revenue Platform Economics Differentiated revenue models support growth, recurring revenue and profitability Patient Services (~60% of revenue, $86M+) Device Solutions (~40% of revenue, $56M+) Primary driver of growth and margin expansion Contracted, infrastructure-based revenue with high visibility
Slide 9: Key Products & Therapies
What We Provide: Key Products & Therapies Essential infrastructure for the high-growth home healthcare delivery market Patient Services – Clinic-to-Home Healthcare Solutions Oncology Infusion Wound Care Pain Management • Ambulatory pumps and disposables • Negative Pressure Wound Therapy • Continuous
Slide 10: Key Products & Therapies: Device Solutions
What We Provide: Key Products & Therapies Device Solutions – Direct-to-Facility Platform Biomedical Services – End-to-End Equipment Device Rentals & Sales Management • Short- and long-term pump rental solutions • Repair, preventative maintenance and certification services • Equipment sales, consumab
Slide 11: Creating Value Across the Healthcare Ecosystem
Creating Value Across the Healthcare Ecosystem Delivering value to each stakeholder supports long-term customer retention Hospitals & Oncology Practices Payers (Insurance Companies) Unlock Clinical Capacity & Improve Economics Lower Total Cost of Care • Shift appropriate therapies to the home • Home
Slide 12: Transitioning From Investment Phase to Accelerated Margin Expansion
Transitioning From Investment Phase to Accelerated Margin Expansion The Catalyst: The Strategy: The Proven Result: $2.6M IT Investment Roll-Off Scaling Revenue Without Scaling Costs Sustainable Margin Profile • Investment Period Complete: Multi-year • Fixed-Cost Scalability: Our national footprint •
Slide 13: Proven Expansion Beyond Oncology
Validation: Proven Expansion Beyond Oncology Wound Care: Established & Scaling Pain Management: Extension of Core Capabilities • Expanded into NPWT, lymphedema therapy, pneumatic • Expanded ambulatory pump platform into pain compression devices and advanced wound care products management therapies •
Slide 14: Our Competitive Moat
Our Competitive Moat Structural advantages across scale, reimbursement and service integration create high barriers to entry and support long-term customer retention Extensive Payer Access • 800+ payer contracts covering 97%+ of U.S. insured lives • Expanding annually across the Big 5 health insurer
Slide 15: Large, Expanding Healthcare Markets
Market Opportunity: Large, Expanding Healthcare Markets Aligned with the shift toward integrated, service-based home healthcare delivery Oncology: Core Market Wound Care: High-Growth Device Solutions: Outsourced & • Large, recurring market driven by increasing Adjacent Market Integrated Services Mar
Slide 16: Three Complementary Growth Engines
Three Complementary Growth Engines Core Growth Expansion Growth Efficiency & Margin Levers Revenue Growth New Verticals Driving Driving Margin Expansion Within the Oncology Platform Incremental Revenue Growth • ERP Complete: Improved billing • Oncology Volume: New hospital • Wound Care: Rapid growth
Slide 17: Executing Against Our Growth Engines
Growth Strategy: Executing Against Our Growth Engines 1. Expansion in Adjacent & High-Growth Therapies • Scale Wound Care across existing and new customers, including NPWT, compression therapy and advanced wound care products • Expand Pain Management leveraging existing ambulatory pump platform • En
Slide 18: Annual Financial Performance
Annual Financial Performance Net Revenues Adjusted EBITDA (2) 6-8 % Proforma $160.0 $40.0 low to mid 20%'s $143.4 143.3 Growth (1) $134.9 of Revenue $140.0 $125.8 $35.0 $31.5 $32.1 $120.0 $109.9 $30.0 $102.4 $25.3 $ in Millions $ in Millions $24.0 $100.0 $25.0 $22.4 $20.7 $80.0 $20.0 $60.0 $15.0 $40
Slide 19: Annual Margin Performance
Annual Margin Performance Gross Margin Adjusted EBITDA Margin (1) 30.0% 57.2% 57.5% low to mid 20%'s 60.0% 55.1% 56.0% 52.2% 23.5% of Revenue 50.2% 25.0% 21.9% 22.4% 50.0% 20.0% 18.9% 17.8% 18.8% 40.0% 15.0% 30.0% 10.0% 20.0% 5.0% 10.0% —% —% 2021 2022 2023 2024(2) 2025(2) TTM Estimated 2021 2022 20
Slide 20: Quarterly Trends
Quarterly Trends Net Revenue Quarterly Trend Adjusted EBITDA Quarterly Trend (1)(2) $40.0 $10.0 $36.9 $36.5 $36.2 $36.0 $34.7 $35.3 $9.0 $8.8 $33.8 $8.6 $33.7 $33.7 $8.3 $32.0 $31.7 $31.9 $31.8 $8.0 $7.9 $30.4 $8.0 $7.5 $30.0 $28.8 $26.8 $27.0 $27.3 $7.0 $6.3$6.4 $6.2 $6.2 $6.1 $5.8 $ in Millions $
Slide 21: Balance Sheet Highlights
Balance Sheet Highlights Fixed vs. Floating Debt $ in Millions As of June 30, 2026 Equity $59.1 Total Long-Term Debt 1 $20.4 2% Net Leverage Ratio 0.61x Debt/Equity Ratio 0.65x Total Available Liquidity $55.2 $20.4M Cash Provided by Operations (TTM) $23.4 Cash (Designed for low cash levels) $1.0 Wor
Slide 22: Leadership
Leadership Experienced leadership driving scalable growth Executive Management Board of Directors • Deep experience in healthcare services, clinical operations and • Public company governance and capital markets expertise reimbursement-driven business models • Experience supporting growth, M&A and d
Slide 23: Capital Markets Snapshot
Capital Markets Snapshot Trading Information Ticker: Exchange: Shares Outstanding: Market Cap: 52-Week Range: INFU NYSE American 19.9M $192.2M $5.41 - $10.79 Balance Sheet & Liquidity Analyst Coverage Total Liquidity: $55.2M (cash + available credit facility) B. Riley Securities Cash & Debt: $1.0M c
Slide 24: Why InfuSystem?
Why InfuSystem? Specialized Healthcare Services Platform with National Scale • 18 of top 20 U.S. hospitals | 800+ payer contracts | 100,000+ device fleet | 40-year foundation Multiple Paths to Profitable Growth • Core: Oncology growth driven by new contracts, pricing improvements and increased utili
Slide 25: Appendix A GAAP to NON-GAAP Reconciliation
Appendix A GAAP to NON-GAAP Reconciliation Twelve Months Ended Three Months Ended Six Months Ended NET INCOME TO ADJUSTED EBITDA: December 31, June 30, June 30, (in thousands) 2022 2023 2024 2025 2025 2026 2025 2026 GAAP net income $ 18 $ 872 $ 2,345 $ 6,627 $ 2,599 $ 3,231 $ 2,332 $ 4,248 Adjustmen
Slide 26: Questions & Answers
Questions & Answers 26
Slide 27: Thank You
Thank You Bristol Capital Ltd. Glen Akselrod & Stefan Eftychiou T: (905) 326-1888 Ext 1 27